Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498349 | 1.00 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL2297578 | 0.89 | DDB1 (0.49) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL12355229 | 0.80 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL560572 | 0.77 | POLB (0.38) | SMN1; SMN2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL560573 | 0.77 | POLB (0.38) | SMN1; SMN2GAAKDM4EALDH1A1MAPT | |
| SCHEMBL2913795 | 0.76 | CTSS (0.55) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL1324347 | 0.76 | DDB1 (0.42) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL1974652 | 0.75 | CTSB (0.51) | CTSSCTSLCTSBNPC1RAB9A | |
| SCHEMBL12424729 | 0.75 | DDB1 (0.47) | DDB1CRBNCTSSCTSLCTSB | |
| SCHEMBL10332172 | 0.74 | CTSS (0.59) | CTSSCTSLCTSBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6192222-A | — | — | None | — | — | JP | disclosed |
| US-9434737-B2 | Process for producing optically active succinimide derivatives and intermediates thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-8900830-B2 | Process for producing optically active succinimide derivatives | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140099681-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | KYOWA HAKKO BIO CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8633001-B2 | Process for producing optically active succinimide derivatives and intermediates thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130196388-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES | KYOWA HAKKO BIO CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8389742-B2 | 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20120034660-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | KYOWA HAKKO BIO CO., LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-2395097-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVE AND INTERMEDIATE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8003808-B2 | 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100004464-A1 | Method for producing succinimide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090253917-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2077261-A1 | METHOD FOR PRODUCING SUCCINIMIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-2071033-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-0520320-B1 | Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1997-09-10 | — | — | EP | disclosed |
| CN-1034176-C | Tetrahydropyrrolo (1,2-a) pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for preparation thereof and pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO (JP) | 1997-03-05 | — | — | CN | disclosed |
| JP-H06192222-A | SUCCINIC ACID IMIDE DERIVATIVE | DAINIPPON PHARMACEUT CO LTD | 1994-07-12 | — | — | JP | disclosed |
| US-5258382-A | Antidiabetic agents or reductase inhibitors | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
| CN-1068825-A | Pyrrolidine is the preparation method of [1,2-a] pyrazine-4-spiral shell-3 ' pyrrolidin derivatives also | DAINIPPON PHARMACEUTICAL CO (JP) | 1993-02-10 | — | — | CN | disclosed |
| EP-0520320-A2 | Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253917-A1 | 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME | SLC5A1, TERT, CBR3 | DDB1 3636/4885CRBN 3259/4885CTSS 4538/4885 |
| US-20140099681-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | SDHA, STS, DHPS | DDB1 3625/4885CRBN 2003/4885CTSS 2527/4885 |
| US-20100004464-A1 | Method for producing succinimide compound | ALDH7A1, SDHB, SDHA | DDB1 4075/4885CRBN 1652/4885CTSS 3907/4885 |
| US-20120034660-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF | SDHA, STS, ALDH18A1 | DDB1 3648/4885CRBN 1752/4885CTSS 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.